IntroductionSars-CoV-2 (severe acute respiratory syndrome coronavirus-2) is an RNA virus that causes Covid-19 disease. This disease started in the city of Wuhan in China. This is not the first time that the coronavirus has caused an outbreak, in the last twenty years the coronavirus SARS-CoV (Severe Acute Respiratory Syndrome coronavirus) and MERSCoV (Middle East Respiratory Syndrome coronavirus) have caused two major outbreaks. The main structure of SARS-CoV-2 is built from membrane (M), envelope (E), nucleocapsid (N) and spike (S). When the body is infected by the virus, the virus enters the host cells by binding to the ACE2 receptor. Once the virus has entered the cell, it releases viral RNA. The virus's particles multiply inside the cell. New virus particles from the infected cell are produced, which in its turn infect new cells. The immune system against SARS-CoV-2 involves both the cellular and humoral arms, with neutralizing antibodies directed primarily against the S antigen.ObjectivesThis research aimed to study the litteratur describing how long the antibodies and memory cells remain in the blood, and how long the protection against the virus lasts.MethodThis work was based on six scientific articles to answer the question: How long protective antibody levels last in the plasma after resolution of a Covid-19 infection? To answer the question, the levels of the antibodies of different classes, IgG, IgM and IgA, against the receptorbinding domain (RBD)/ S, N protein were analysed as reported in litterature, as well as the reported amounts of T memory cells and B memory cells.ResultsHumans produce SARS-CoV-2-specific antibodies, especially IgM and IgG antibodies, and T cells response to SARS-CoV-2 infection. IgG and IgM antibody levels were higher in patients whith severe Covid-19 than in mild cases. Studies cohort included patients from 18 to 90 years old. The studies lasted on from three months and up to one year.

Contexte : Partout dans le monde, la population âgée en hébergement a été la plus lourdement affectée par la pandémie de COVID-19, du point de vue des infections et des décès. Or, ces mêmes personnes ont été exclues d’une grande partie de la littérature scientifique. Ce mémoire décrit l’évolution des éclosions dans 17 CHSLD publics de Montréal, dont certains ont été fortement atteints alors que d’autres ont été épargnés pendant la première vague (23 février au 11 juillet 2020), en cherchant à élucider les facteurs associés à l’incidence et à la létalité de la COVID-19. Méthodes : Des données institutionnelles ont été recueillies sur les 17 CHSLD du CIUSSS Centre-Sud-de-l'Île-de-Montréal et des données individuelles ont été obtenues grâce à une révision des 1197 dossiers de patients atteints de la COVID-19 en première vague. Dans l’analyse ARIMA, des séries chronologiques ont été construites pour les cas incidents bruts chez les résidents en CHSLD et dans la ville de Montréal, afin d’évaluer l’impact de deux interventions, soit le port généralisé du masque de procédure et le dépistage élargi des résidents et des employés. Dans l’analyse des infections par CHSLD, des modèles de régression de type binomial négatif ont été construits pour estimer l’effet des facteurs de risque institutionnels sur l’incidence de la COVID-19 chez les résidents. Dans l’analyse de surmortalité, les excès de décès durant la période de février à juillet ont été évalués avec des tests t et des ratios de taux entre l’année 2020 et la moyenne des quatre années précédentes (2016-2019). Enfin, pour l’analyse de mortalité dans la cohorte rétrospective de résidents atteints de la COVID-19, des modèles de régression logistique à effets mixtes ont été utilisés pour évaluer les facteurs institutionnels et les traitements associés à la mortalité dans les 30 jours suivant un diagnostic de COVID-19, en contrôlant pour les facteurs de risque individuels. Résultats : Dans l’analyse de série chronologique ARIMA, chaque augmentation d’un cas incident quotidien par 100 000 à Montréal était associée avec une augmentation de 0,051 (IC95% 0,044 à 0,058) fois l’incidence quotidienne en CHSLD la semaine suivante, chez les résidents à risque. De plus, en contrôlant pour la transmission communautaire, chaque palier d’intensification du dépistage était associé à une diminution de l’incidence de 11,8 fois (IC95% -15,1 à -8,5) dans les deux semaines suivantes, chez les résidents à risque. Dans le modèle explicatif des infections au niveau des CHSLD, la pénurie sévère d’infirmières auxiliaires (IRR 3,2; IC95% 1,4 à 7,2), la mauvaise performance aux audits ministériels (IRR 3,0; IC95% 1,1 à 7,8) et un score moyen d’autonomie plus faible (IRR 2,1; IC95% 1,4 à 3,1) étaient associés au taux d’incidence par centre. En revanche, la présence de zone chaude dédiée aux patients COVID-19 (IRR; 0,56 IC95% 0,34 à 0,92) était protectrice. Pour l’ensemble des 17 CHSLD avec 2670 lits, l’excès de décès de février à juillet 2020 était de 428 (IC95% 409 à 447). Comparé aux quatre années précédentes, il y a eu plus que le double (IRR 2,3; IC95% 2,1 à 2,5) de décès en 2020 pendant la période de la première vague. Pour 12 CHSLD qui ont vécu des éclosions importantes, les excès de décès en 2020 variaient de 5,2 à 41,9 décès par 100 lits, avec une surmortalité par rapport aux années précédentes allant de 1,9 à 3,8. Selon l’analyse de mortalité dans la cohorte rétrospective, les facteurs individuels associés à la mortalité dans les 30 jours suivant le diagnostic de COVID-19 étaient l’âge (OR 1,58; IC95% 1,35 à 1,85 par tranche additionnelle de 10 ans), le sexe masculin (OR 2,37; IC95% 1,70 à 3,32), la perte d’autonomie (OR 1,12; IC95% 1,05 à 1,20 pour chaque augmentation d’un point à l’Iso-SMAF), le niveau d’intervention médicale C (OR 3,43; IC95% 1,57 à 7,51) et D (OR 3,61; IC95% 1,47 à 8,89) comparé au niveau A, ainsi que les diagnostics de trouble neurocognitif (OR 1,54; IC95% 1,04 à 2,29) et d’insuffisance cardiaque (OR 2,36; IC95% 1,45 à 3,85). Le traitement avec une thromboprophylaxie (OR 0,42; IC95% 0,29 à 0,63) et l’infection tardive après le 20 avril 2020 (OR 0,46; IC95% 0,33 à 0,65) étaient associés à la survie à 30 jours. Pour les facteurs institutionnels, la pénurie sévère de 25% ou plus d’infirmières auxiliaires (OR 1,91; IC95% 1,14 à 3,21 par rapport à une pénurie légère < 15%) et la taille du centre (OR 1,77; IC95% 1,17 à 2,68 pour chaque 100 lits additionnels) étaient associés au décès dans les 30 jours. Conclusion : Ce mémoire a relevé plusieurs facteurs de risque modifiables au niveau institutionnel associés aux infections et aux décès COVID-19, dont le dépistage, l’adhérence aux directives ministérielles de prévention et contrôle des infections, la pénurie d’infirmières auxiliaires et le nombre de lits par centre. Ces enjeux cruciaux devront être au cœur des futures orientations et politiques touchant les centres d’hébergement, pour cette pandémie et au-delà. / Background: In the midst of the COVID-19 pandemic, the population of long-term care residents has been the hardest hit by infections and deaths all around the world. Yet, these same individuals have been excluded from vast segments of the scientific literature. This thesis describes the evolution of outbreaks in 17 public long-term care facilities (“CHSLD”) in Montreal, some of which were severely affected and others were relatively spared during the first wave (February 23 to July 12, 2020), in search of risk factors associated with COVID-19 cases and deaths. Methods: Institutional-level data on the 17 CHSLDs were collected from relevant administrative departments within the establishment (CIUSSS Centre-Sud-de-l'Île-de-Montréal), and individual-level data was obtained from the chart reviews of 1,197 first wave COVID-19 patients. For the ARIMA analysis, time series were built using the crude incidence rates among CHSLD residents and in the city of Montreal, in order to assess the impact of two interventions – introduction of the mask-wearing policy and generalized testing among residents and staff. For the analysis of facility-level infection rates, negative binomial regression models were built to estimate the effects of several institutional risk factors on incident cases. As for the excess mortality analysis, excess death and relative mortality were estimated using one-sample t-tests and rate ratio tests to compare 2020 deaths with average deaths in the previous four years (2016-2019), for the period of February to July. Lastly, for the survival analysis of the retrospective cohort, mixed-effects logistic regression models were used to identify institutional factors and treatments associated with 30-day mortality after a COVID-19 diagnosis, while controlling for individual risk factors. Results: In the ARIMA time series analysis, each additional case per 100,000 per day in Montreal was associated with a 0.051 (95%CI 0.044 to 0.058) increase in CHSLD daily incidence a week later, among at-risk residents. In addition, while controlling for community transmission, increased testing intensity was associated with a 11.8 (95%CI -15.1 to -8.5) decrease in CHSLD daily incidence two weeks later, among at-risk residents. In the negative binomial regression model for facility-level COVID-19 infections, poor performance on ministry audits (IRR 3.0 95%CI 1.1 to 7.8), severe shortage of auxiliary nurses (IRR 3.2 95%CI 1.4 to 7.2) and lower average autonomy scores (IRR 2.1 95%CI 1.4 to 3.1) were associated with incident cases, while the presence of a COVID-19 unit or “red zone” (IRR 0.56 95%CI 0.34 to 0.92) was inversely associated with infections. For the 17 CHSLDs, excess deaths from February to July 2020 was 428 (95%CI 409 to 447). Compared to the same period in the previous four years, 2020 mortality during the first wave was 2.3 (IRR 95%CI 2.1 to 2.5) times higher. For a subset of 12 facilities that experienced substantial outbreaks, excess deaths in 2020 varied from 5.2 to 41.9 deaths per 100 beds, with significant excess mortality between 1.9 and 3.8, relative to previous years. According to the mortality analysis by mixed-effects logistic regression, individual risk factors associated with 30-day mortality after a COVID-19 diagnosis were age (OR 1.58 95%CI 1.35 to 1.85 per additional 10 years), male sex (OR 2.37 95%CI 1.70 to 3.32), loss of autonomy (OR 1.12 95%CI 1.05 to 1.20 per unit increase of Iso-SMAF profile), C-level (OR 3.43 95%CI 1.57 to 7.51) or D-level (OR 3.61 95%CI 1.47 to 8.89) medical intervention compared to A-level, as well as being diagnosed with a neurocognitive disorder (OR 1.54 95%CI 1.04 to 2.29) or congestive heart failure (OR 2.36 95%CI 1.45 to 3.85). Treatment with thromboprophylaxis (OR 0.42 95%CI 0.29 to 0.63) and diagnosis after April 20, 2020 (OR 0.46 95%CI 0.33 to 0.65) were associated with 30-day survival. As for institutional risk factors, severe shortage of auxiliary nurses (OR 1.91 95%CI 1.14 to 3.21) and facility size (OR 1.77 95%CI 1.17 to 2.68 per 100 beds) increased the odds of dying within 30 days. Conclusion: This study identified several modifiable risk factors at the institutional level associated with COVID-19 infections and deaths, including testing strategies, adherence to ministry directives for infection prevention, auxiliary nurse shortages, and number of beds per facility. Future policies and regulations targeting long-term care facilities will need to tackle these critical issues, for this pandemic and beyond.

Coronavirus disease 2019 (COVID-19), an infectious respiratory disease propagated by a new virus known as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has resulted in global healthcare crises. Emerging evidence from patients with COVID-19 suggests that endothelial cell damage plays a central role in COVID-19 pathogenesis and could be a major contributor to the severity and mortality of COVID-19. Like other infectious diseases, the pathogenesis of COVID-19 is closely associated with metabolic processes. Lactate, a potential biomarker in COVID-19, has recently been shown to mediate endothelial barrier dysfunction. In this review, we provide an overview of cardiovascular injuries and metabolic alterations caused by SARS-CoV-2 infection. We also propose that lactate plays a potential role in COVID-19-driven endothelial cell injury.

No description available.

<p> Virus-induced modulation of dendritic cell function is thought to be an effective mechanism for viral-immune evasion. The severe-acute respiratory syndrome coronavirus (SARS-CoV) has been shown to infected human myeloid dendritic cells (MDCs) and directly modulate the cellular cytokine production. The ability of other human coronaviruses to infect MDCs and impair cell immune function has not been assessed. </p> <p> This thesis describes the infection of human MDCs with coronavirus 229E, NL63, and OC43. 229E showed productive, but limited genomic replication, nucleocapsid protein synthesis and infectious progeny release in MDCs. 229E infection stimulated IFN-α, IL-6 and MCP-1 production in MDCs, but little to no IL-12, TNF-α, IL-8, IP-10, or RANTES . 229E-infected MDCs showed poor CD80 expression, down-regulated CD86 and HLA-DR expression and were poor stimulators of CD4+ T cell proliferation. In contrast to 229E, OC43 showed persistent and productive genomic replication, nucleocapsid protein synthesis and infectious progeny release in MDCs. OC43 infection stimulated IFN-α, IL-12, IP-10 and MCP-1 production in MDCs, but little to no TNF-α, IL-6, IL-8 or RANTES . The up-regulation of maturation molecules and CD4+ T cell stimulatory capacity in OC43-infected MDCs was donor cell-dependent. In contrast to 229E and OC43, NL63 infection of MDCs was non-productive, showing no viral genomic replication, protein production or infectious progeny release. NL63 infection stimulated strong cytokine (IFN-α, IL-12, TNF-β and IL-6) and chemokine (IL-8, IP-10, RANTES and MCP-1) responses in MDCs. NL63-infected MDCs showed up-regulated CD80, CD83, CD86 and HLA-DR expression and were efficient stimulators of CD4+ T cell proliferation. </p> <p> This study provides the first evidence that human coronaviruses other than SARSCo V can abrogate MDC immune effector function. It also provides the first side-by-side comparison of 229E, NL63 and OC43 and identifies the potential of 229E and OC43 to impair MDC cytokine production and T cell stimulation as a mechanism of immune response evasion. <p> / Thesis / Doctor of Philosophy (PhD)

<p dir="ltr">Infectious diseases are caused by a multitude of organisms, ranging from viruses to bacteria, from parasites to fungi, and can be passed directly or indirectly from one person to another. Further, they continue to be a leading cause of death, especially in low-resource countries, thereby emphasizing the need for continued investigation. Understanding transmission of such diseases is vital as management or prevention of outbreaks through detection, reporting, isolation, and case management are ever-evolving. One way by which scientists can study infectious diseases is through a combination of epidemiological, genomic, and evolutionary biology approaches. This doctoral research occurred precisely at this interface, spanning across the fields of genomics, molecular biology, and epidemiology, as applied to the study of infectious disease dynamics of two separate pathogen systems (protozoan and virus).</p><p dir="ltr">The first half of this research (Chapters 1 + 2) involved the implementation of SARS-CoV-2 genomic sequencing and surveillance at Purdue University. Through this investigation in a university setting (Chapter 1), this work identified relevant variants of concern in hundreds of newly sequenced viral genomes and compared variant temporal trends with other similar university settings using publicly available data. Further phylodynamic analysis of Gamma (P.1) genomes from campus revealed multiple introductions into the Purdue community, predominantly from states within the United States. A second study (Chapter 2) assessed the transmission of variants over the course of an entire academic year from 2021-2022 in Purdue’s highly vaccinated community. This research described the rapid transition from Delta to Omicron variants and investigated variant introduction events into the campus. This comprehensive analysis showed that robust surveillance programs coupled with viral genomic sequencing and phylogenetic analysis can provide critical insights into SARS-CoV-2 spread and can help inform mitigation strategies for future pandemics.</p><p dir="ltr">The latter half of this body of research (Chapters 3 + 4) focused on malaria, which is a disease caused by <i>Plasmodium </i>species<i> </i>parasites and transmitted to humans through the bites of infected mosquitoes. The first investigation explored diagnostic accuracy metrics across a malaria transmission gradient in Zambia through a comparison of the diagnostic performance of Rapid Diagnostic Tests (RDT) and Light Microscopy (LM) with photo-induced electron transfer polymerase chain reaction (PET-PCR) as the gold standard using 2018 Malaria Indicator Survey (MIS) data. Results suggested that RDTs and LM both performed well across a range of transmission intensities, but low parasitaemia infections can affect accuracy. This suggests that more sensitive tools should be utilized to identify the last cases as Zambia moves towards malaria elimination. In addition to diagnostic metrics, preventing disease is also crucial for infectious diseases, and vaccines present one mechanism by which this can be done. Research to develop a malaria vaccine with sustained high efficacy has spanned decade. However, the process has proven to be challenging, with several vaccine candidates having advanced to early-stage trials, but only a few demonstrating sustained efficacy in clinical testing. The goal of the last investigation (Chapter 4) was to shed light on the diversity of <i>Plasmodium falciparum </i>antigens which could be considered when developing future malaria vaccines. Results of evolutionary and genomic analyses of Whole-Genome-Sequences from Zambia and other countries in Africa suggest that conserved merozoite antigens and/or transmission-blocking antigens should be prioritized when developing future malaria vaccines.</p>

40% of severe acute respiratory syndrome coronavirus two (SARS-CoV-2) severe cases develop acute kidney injury (AKI). Current treatment for renal complications limits financial and material resources available. To explore alternative treatments and accelerate research in case of future coronavirus outbreaks, a mouse model of coronavirus disease 2019-associated AKI (C19-AKI) would represent a critical biomedical research tool. The surrogate model of C19-AKI (SMC) developed consisted of angiotensin-converting enzyme two (ACE2) knockout (KO) mice receiving 400 ng/kg/min of angiotensin (Ang) II by osmotic minipump for eight days with a single injection of lipopolysaccharide (LPS; 10 mg/kg) on the seventh day of Ang II and euthanasia 24 hours after LPS. Similarly, to C19-AKI, the SMC exhibited albuminuria, elevated blood urea nitrogen, electrolyte imbalance, neutrophil infiltration, and upregulation of the G-coupled protein receptor (GPR)84 and pro-inflammatory and injury markers. GPR84 was found in bronchoalveolar lavage fluid neutrophils of coronavirus disease 2019 (COVID-19) patients, suggesting a potential implication of GPR84 in the disease. We hypothesised that GPR84 deletion or antagonism with GLPG-1205 could attenuate SMC’s indices of renal injury and inflammation. GLPG-1205 and GPR84 KO had no effects in the SMC model, as suggested by unchanged albuminuria, electrolytes, and markers expression. Interestingly, neutrophil infiltration was attenuated by GLPG-1205 only. The SMC is an interesting tool for therapeutic development for infections associated with renal injury, such as SARS-CoV-2. GPR84 role in the SMC needs to be further assessed.

Después de la pandemia más conocida como la gripe española del año 1918, no hubo otra capaz de poner en serios problemas la economía mundial, en especial los mercados de valores de todos los países hasta la llegada del nuevo coronavirus SARS-COV2, denominado también COVID19. Por ello, el presente trabajo busca analizar y comparar los efectos de dos pandemias ocurridas en el periodo 2008-2020 en los mercados de renta de variable. Estas pandemias son la gripe A(H1N1) ocurrida en el periodo 2009- 2011 y el nuevo coronavirus SARS-COV2 que inició a finales del 2019 en Wuhan, China. El periodo de análisis para el SARS-COV2 será 2009-2020. Se plantea que para las Bolsas de Valores de los países desarrollados (EE.UU, China y España) existirá un impacto negativo sobre el rendimiento asociado a dichas bolsas ante la presencia del COVID-19 en el corto y mediano plazo; esto a su vez desencadenará un efecto en cadena similar o incluso mayor sobre las Bolsas de Valores de los países que conforman el MILA (Mercado Integrado Latinoamericano) Perú, Chile y Colombia. Este impacto sería de mayor escala que el impacto ocasionado por la gripe A (H1N1) pdm09, debido a que se considera que la crisis financiera internacional del año 2008 fue el determinante de la caída de las bolsas de valores de Estados Unidos, España y de los países en desarrollo en ese periodo. En esta investigación se va a utilizar un modelo Panel Least Squares para poder estimar los efectos de las pandemias en los índices de rendimiento de los países mencionados / After the pandemic better known as the Spanish flu of 1918, there was no other capable of putting the world economy, especially the stock markets of all countries, in serious trouble until the arrival of the new SARS-COV2 coronavirus, also called COVID19. For this reason, the present research seeks to analyze and compare the effects of two pandemics that occurred in the 2008-2020 period in the equity markets. These pandemics are influenza A (H1N1) that occurred in the 2009-2011 period and the new SARS-COV2 coronavirus that started in late 2019 in Wuhan, China. The analysis period for SARS-COV2 will be 2009-2020. It is proposed that for the Stock Exchanges of developed countries (USA, China and Spain) there will be a negative impact on the performance associated with these exchanges in the presence of COVID-19 in the short and medium term; this in turn will unleash a similar or even greater chain effect on the Stock Exchanges of the countries that make up the MILA (Latin American Integrated Market) Peru, Chile and Colombia. This impact would be of a larger scale than the impact caused by influenza A (H1N1) pdm09, because it is considered that the international financial crisis of 2008 was the determinant of the fall of the stock markets of the United States, Spain and developing countries in that period. In this research, a Panel Least Squares model will be used to estimate the effects of pandemics on the performance indexes of the mentioned countries.

Tesis por compendio / [ES] Los oligosacáridos de la leche humana (OLHs) y la parte glicana de los glicoconjugados son hidrolizados por las glicosil hidrolasas (GHs), las cuales son expresadas por la microbiota intestinal de niños lactantes promoviendo el establecimiento de una microbiota intestinal con beneficios para su salud. El objetivo de esta Tesis Doctoral consistió en la caracterización funcional de GHs de la microbiota intestinal de niños lactantes capaces de metabolizar OLHs y glicoconjugados, y el estudio de su relevancia biológica y su potencial biotecnológico. Se aislaron cepas bacterianas a partir de heces de niños lactantes.Solo las cepas del género Bifidobacterium metabolizaron alguno de los OLHs testados. Bifidobacterium infantis Y538 consumió eficientemente todos los OLHs testados, mientras que las dos cepas de Bifidobacterium dentium Y510 y Y521 solo metabolizaron lacto-N-tetraosa (LNT) y lacto-N-neotetraosa (LNnT). Se caracterizaron dos ß-galactosidasas de B. dentium Y510; Bdg42A mostró la mayor actividad en LNT, hidrolizándolo en galactosa y lacto-N-triosa (LNTII), mientras que Bdg2A mostró actividad contra lactosa, 6'-galactopiranósil-N-acetilglucosamina, N-acetillactosamina y LNnT. También se aislaron cepas bacterianas con actividad glicosidasa extracelular de las heces de lactantes. B. infantis E17 y E18, y Enterococcus faecalis E8 y E41 exhibieron actividad de endo-ß-N-acetilglucosaminidasa, liberando N-glicanos de glicoproteínas. La endo-ß-N-acetilglucosaminidasa EndoE de E. faecalis E8 deglicosiló eficientemente la proteína S1 del coronavirus 2 del síndrome respiratorio agudo severo (SARS-CoV-2). Tanto la EndoE silvestre como un mutante catalíticamente inactive mostraron actividad lectina frente a la proteína S1 y actividad neutralizante frente a la infección de un virus pseudotipado que presenta la proteína S de SARS-CoV-2 expresada. También se identificaron GHs putativas a través del análisis metagenómico de las heces de niños lactantes, pertenecientes a los géneros Bifidobacterium, Bacteroides, Ruminococcus, Actinomyces, Klebsiella, Phocaeicola y Streptococcus. Se seleccionaron diez ¿-L-fucosidasas GH29 (Fuc18, Fuc19A, Fuc30, Fuc35A, Fuc35B, Fuc39, Fuc193, Fuc1584, Fuc2358 y Fuc5372). Las ¿-L-fucosidasas Fuc18, Fuc19A, Fuc35B, Fuc39 y Fuc1584 mostraron actividad hidrolítica frente a enlaces de fucosa ¿-1,3/4 y Fuc35A, Fuc193 y Fuc2358 mostraron actividad enlaces de fucosa ¿-1,2/3/4/6. Fuc30 mostró actividad sobre la enlaces de fucosa ¿-1,6 mientras que Fuc5372 mostró preferencia por los enlaces ¿-1,2. Fuc2358 mostró actividad frente a glicoconjugados con lacto-N-fucopentaosa II, lacto-N-fucopentaosa III y contra la mucina. Fuc18, Fuc19A y Fuc39 eliminaron fucosa de neoglicoproteínas y de la glicoproteína ¿-1 ácida. Las ¿-L-fucosidasas aisladas fueron evaluadas por su capacidad para sintetizar fucosil-oligosacáridos (FUS) a través de reacciones de transfucosilación. Fuc2358 produjo rendimientos del 35% de 2'-fucosillactosa (2'FL) y también 3'-fucosillactosa (3'FL) y 1-fucosillactosa (1FL). Fuc5372 sintetizó 2'FL, 3'FL y 1FL, con una proporción más alta de 3'FL. Se llevó a cabo mutagénesis dirigida para aumentar los rendimientos de transfucosilación. Los mutantes Fuc2358-H132F, Fuc2358-F184H, Fuc2358-R301Q, Fuc2358-K286R y Fuc5372-R230K mostraron una mayor relación entre la 2'FL producida y el pNP-Fuc hidrolizado que sus respectivas enzimas silvestres. Además, se observó que los residuos F184 de Fuc2358 y W151 de Fuc5378 afectan a la regioselectividad de la transfucosilación, la fenilalanina aumentando la selectividad por los enlaces ¿-1,2 y el triptófano aumentando la selectividad por los enlaces ¿-1,3. Los resultados presentados muestran la diversidad de GHs presentes en la microbiota intestinal de niños lactantes y expanden el conocimiento sobre su especificidad, contribuyendo al conocimiento del posible papel de las GHs en la colonización bacteriana del tracto gastrointestinal y, además, muestra su potencial biotecnológico / [CA] Els oligosacàrids de la llet humana (OLHs) i la part glicana de glicoconjugats són hidrolitzats per les glicosil hidrolases (GHs), les quals són expressades per la microbiota intestinal de xiquets lactants, promovent l'establiment d'una microbiota intestinal amb beneficis per a la seua salut. L'objectiu d'aquesta Tesi Doctoral va ser la caracterització funcional de GHs de la microbiota intestinal de xiquets lactants capaços de metabolitzar OLHs i glicoconjugats i l'estudi de la seua rellevància biològica i el seu potencial biotecnològic. Es van aïllar soques bacterianes a partir de les femtes de xiquets lactants. Només els soques del gènere Bifidobacterium van metabolitzar algun dels OLHs testats. Bifidobacterium infantis Y538 va consumir eficientment tots els OLHs testats. Les dos soques de Bifidobacterium dentium Y510 i Y521 sol van metabolitzar lacto-N-tetraosa (LNT) i lacto-N-neotetraosa (LNnT).Es van caracteritzar dos ß-galactosidasas de B. dentium Y510; Bdg42A va exhibir la major activitat enfront de LNT, hidrolitzant-la en galactosa i lacto-N-triosa (LNTII), mentre que Bdg2A va mostrar activitat enfront de lactosa, 6'-galactopiranósil-N-acetilglucosamina, N-acetillactosamina i LNnT. També es van aïllar soques bacterianes amb activitat glicosidasa extracelul·lar. B. infantis E17 i E18, i Enterococcus faecalis E8 i E41 van exhibir activitat endo-ß-N-acetilglucosaminidasa, alliberant N-glicans de glicoproteïnes. La endo-ß-N-acetilglucosaminidasa EndoE de E. faecalis E8 va deglicosilar eficientment la proteïna S1 del coronavirus 2 del síndrome respiratori agut greu (SARS-CoV-2).Tant la EndoE salvatge com un mutant catalíticament inactiu van mostrar activitat lectina enfront de la proteïna S1 i activitat neutralitzador enfront de la infecció d'un virus pseudotipat que presenta la proteïna S de SARS-CoV-2 expressada. També es van identificar GHs putatives a través de l'anàlisi metagenómic de la femta de xiquets lactants, pertanyents als gèneres Bifidobacterium, Bacteroides, Ruminococcus, Actinomyces, Klebsiella, Phocaeicola i Streptococcus. Es van seleccionar deu ¿-L-fucosidasas GH29 (Fuc18, Fuc19A, Fuc30, Fuc35A, Fuc35B, Fuc39, Fuc193, Fuc1584, Fuc2358 i Fuc5372). Les ¿-L-fucosidasas Fuc18, Fuc19A, Fuc35B, Fuc39 i Fuc1584 van mostrar activitat hidrolítica enfront d'enllaços de fucosa ¿-1,3/4 i Fuc35A, Fuc193 i Fuc2358 van mostrar activitat enllaços de fucosa ¿-1,2/3/4/6. Fuc30 va mostrar activitat enfront d'enllaços de fucosa ¿-1,6 mentre que Fuc5372 va mostrar preferència pels enllaços ¿-1,2. Fuc2358 va mostrar activitat enfront de glicoconjugats amb lacto-N-fucopentaosa II, lacto-N-fucopentaosa III i contra la glicoproteïna de la mucina. Fuc18, Fuc19A i Fuc39 van eliminar fucosa de neoglicoproteïnes i de la glicoproteïna ¿-1 àcida. Les ¿-L-fucosidasas aïllades van ser avaluades per la seua capacitat per a sintetitzar fucosil-oligosacàrids (FUS) mediant reaccions de transfucosilació. Fuc2358 va produir rendiments del 35% de 2'-fucosillactosa (2'FL) i també 3'-fucosillactosa (3'FL) i 1-fucosillactosa (1FL). Fuc5372 va sintetitzar 2'FL, 3'FL i 1FL, amb una proporció més alta de 3'FL. Es va dur a terme mutagénesis dirigida per a augmentar els rendiments de transfucosilación. Els mutants Fuc2358-H132F, Fuc2358-F184H, Fuc2358-R301Q, Fuc2358-K286R i Fuc5372-R230K van mostrar una major relació entre la 2'FL produïda i el pNP-Fuc hidrolitzat que els seus respectius enzims salvatges.A més, els residus F184 de Fuc2358 i W151 de Fuc5378 afecten la regioselectivitat de la transfucosilación; la fenilalanina augmenta la selectivitat pels enllaços ¿-1,2 i el triptòfan augmenta la selectivitat pels enllaços ¿-1,3. Els resultats presentats mostren la diversitat de GHs presents en la microbiota intestinal de xiquets lactants i expandixen el coneixement sobre la seua especificitat, contribuint al coneixement del possible paper de les GHs en la colonització bacteriana del tracte gastrointestinal i, a més, mostra el seu potencial biotecnològic. / [EN] Human milk oligosaccharides (HMOs) and the glycan portion of glycoconjugates are hydrolyzed by glycoside hydrolases (GHs) that are expressed by the neonatal intestinal microbiota, promoting the establishment of an intestinal microbiota with health benefits for infants. The objective of this Doctoral Thesis consisted of the functional characterization of GHs from the intestinal microbiota of breastfed infants capable of metabolizing HMOs and glycoconjugates and the study of their biological relevance and their biotechnological potential. Bacterial strains were isolated from breastfed infant faeces, showing that only Bifidobacterium genus strains metabolized any of the HMOs tested. Bifidobacterium infantis Y538 efficiently consumed all tested HMOs, while the two strains isolated from Bifidobacterium dentium Y510 and Y521 only metabolized lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT). Two ß-galactosidases from B. dentium Y510 were characterized; Bdg42A exhibited the highest activity on LNT, hydrolyzing it into galactose and lacto-N-triose (LNTII), while Bdg2A displayed activity against lactose, 6'-galactopyranosyl-N-acetylglucosamine, N-acetyllactosamine and LNnT. Bacterial strains with extracellular glycosidase activity were also isolated from breastfed infant faeces. B. infantis E17 and E18, and Enterococcus faecalis E8 and E41 exhibited endo-ß-N-acetylglucosaminidase activity, releasing N-glycans from glycoproteins. The endo-ß-N-acetylglucosaminidase EndoE from E. faecalis E8 efficiently deglycosylated the spike S1 protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both the EndoE wild-type and a catalytically inactive mutant exhibited lectin activity towards the S1 protein and neutralizing activity against SARS-CoV-2 S pseudotyped virus infection. Putative GHs were also identified through metagenomic analysis of breastfed infant faeces, belonging to Bifidobacterium, Bacteroides, Ruminococcus, Actinomyces, Klebsiella, Phocaeicola, and Streptococcus genera. Ten ¿-L-fucosidases GH29 (Fuc18, Fuc19A, Fuc30, Fuc35A, Fuc35B, Fuc39, Fuc193, Fuc1584, Fuc2358, and Fuc5372) were selected. The ¿-L-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on ¿-1,3/4-linked fucose and Fuc35A, Fuc193 and Fuc2358 showed activity on ¿-1,2/3/4/6-linked fucose. Fuc30 displayed activity only on ¿-1,6-linked fucose, and Fuc5372 showed a preference for ¿-1,2-linked fucose. Fuc2358 displayed activity against glycoconjugates carrying lacto-N-fucopentaose II, lacto-N-fucopentaose III and against the mucin glycoprotein. Fuc18, Fuc19A, and Fuc39 removed fucose from neoglycoproteins and human ¿-1 acid glycoprotein. The isolated ¿-L-fucosidases were evaluated for their capacity to synthesize fucosyl-oligosaccharides (FUS) through transfucosylation reactions. Fuc2358 produced 35 % yields of 2'-fucosyllactose (2'FL) and also 3'-fucosyllactose (3'FL) and 1-fucosyllactose (1FL). Fuc5372 synthesized 2'FL, 3'FL and 1FL, with a higher proportion of 3'FL. Site-directed mutagenesis was conducted to increase the transglycosylation yields. Mutants Fuc2358-H132F, Fuc2358-F184H, Fuc2358-R301Q, Fuc2358-K286R and Fuc5372-R230K showed a higher ratio between 2'FL yields and hydrolyzed pNP-Fuc than their respective wild-type enzymes. The transfucosylation activity results also showed that the residues F184 of Fuc2358 and W151 of Fuc5378 affect transfucosylation regioselectivity, with phenylalanine increasing the selectivity for ¿-1,2 linkages and tryptophan for ¿-1,3 linkages. The results presented in this doctoral thesis illustrate the diversity of GHs in the intestinal microbiota of breastfed infants and have expanded our knowledge of their specificities, which could contribute to a better understanding of the possible role of GHs in the bacterial colonization of the infant gastrointestinal tract and presents significant biotechnological potential. / This work is part of the Grant PID2020-115403RB (C21 and C22) funded by the Spanish Ministry of Science and Innovation (MICIN)/Spanish State Research Agency (AEI)/10.13039/501100011033. The study was also supported by Valencian Government grant AICO/2021/033. EMM-G was supported by the Grant PRE2018-085768 funded by MICIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”. / Moya Gonzálvez, EM. (2024). Isolation, Functional Characterization and Biotechnological Applications of Glycoside Hydrolases from the Intestinal Microbiota of Breastfed Infants [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/203171 / Compendio

Synthesizing proteins for use in therapeutics is restrained by, in part, contaminants in in vivo expression systems and limited production capacity of in vitro systems. Cell free expression (CFE) systems have emerged as a potential alternative for protein expression because of the inherently lower contents of contaminants, and their flexible modular design that allows the addition of factors that aid in synthesis of complex products. Here, we investigate and establish an in-house Escherichia coli-based cell free protein synthesis (CFPS) system, explore different CFPS commercial kits, develop assays to test performance of these systems and identify potential rules that dictate expression levels. Using CFE, we were able to test different vectors and conditions of system, as well as scale-up protein synthesis reactions. In conclusion, this work shows that CFPS is a functional and easy-to-use platform and can potentially meet the requirements for the synthesis of therapeutics.